Apex Biotech Ltd to invest $18 million for a new drug plant in Rwanda
Apex Biotech Ltd, a pharmaceutical manufacturing firm will open an $18 million drug plant in Rwanda.
It will become the second drug plant in Rwanda after Moroccan based Cooper Pharma.
The plant will manufacture generic pharmaceutical formulations in all major therapeutics in a variety of dosage forms including tablets, capsules, powder for suspension (PFS), liquid syrups and oral rehydration therapy.
This project to be built in two phases involves the establishment of a state-of-the-art GMP-compliant pharmaceutical manufacturing plant with an annual capacity of 800 million pcs of tablets, 200 million capsules, 8 million bottles and 5 million ORT sachets at optimum capacity utilization.
Herbeton Madari, the Managing Director of Apex Biotech Pharmaceutical-Rwanda said that the firm will advance science for life in the country and provide “high-quality and affordable” medicine that compliments Rwanda’s life expectancy mark and boosting economic growth.
“Our products and technologies will be used to prevent and treat a wide range of medical conditions, including malaria, HIV/AIDS, TB, Hepatitis as well as non-communicable diseases like heart diseases, diabetes, malnutrition, women’s and children’s health and chronic pain conditions,” said Namzul Ahasan Sarker, the managing director of Bangladesh-based Health City.
Dr. Diane Gashumba said the Minister of Health, this will go a long way in reducing foreign exchange Rwanda invests in importing medicines, create jobs as well as improve the quality of healthcare in Rwanda.
Apex Biotech Ltd is co-owned by Rwandans and Bangladeshi investors. The drug plant is expected to open within the next nine months.